- Location
- Montréal, Canada
''Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement''
http://www.quibd.com/status-update/...copic-response-rates-histological-improvement
Posted on August 31, 2017
Vancouver, British Columbia – August 2nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high clinical and endoscopic response rates in its recently completed Phase 2, open-label, dose ranging trial in study participants with moderate to severe Ulcerative Colitis. In the study, 8 of 11 (73%) QBECO SSI treated participants achieved clinical response and 5 patients (45%) had endoscopic healing within the first 16 weeks of treatment with one patient in clinical and endoscopic remission by study week 8[1]. Importantly, histological improvement occurred in 6 of 11 (55%) trial participants, including 6 of 8 (75%) responders.
Dr. Hal Gunn, CEO of Qu Biologics, commented, “While this is a small study, we are very encouraged by the clinical and endoscopic responses that were achieved in patients treated with QBECO SSI. We are particularly excited about the endoscopic and histological responses that were observed as it appears that QBECO SSI treatment can result in symptom relief and healing at the mucosal and tissue levels.” Dr. Gunn added, “Research has demonstrated that histological improvement is correlated with improved long-term outcome in ulcerative colitis, including reduction in hospitalizations and surgery, and so we are particularly pleased that our novel treatment may have long lasting therapeutic impact in this challenging disease.”
As Jim Pankovich, Qu Biologics’ VP Clinical Operations and Drug Development noted, “This study is the first indication that treatment with QBECO SSI can result in clinical, endoscopic and histological improvement, all important outcome criteria in our ulcerative colitis program and overall inflammatory bowel disease development program. “
These data add to the body of knowledge and understanding Qu Biologics is generating about the use of QBECO SSI for the treatment of inflammatory bowel disease. Further data evaluation from the study is ongoing, including analysis of immune marker changes and correlation between patient genetics and response to QBECO treatment.
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.
http://www.quibd.com/status-update/...copic-response-rates-histological-improvement
Posted on August 31, 2017
Vancouver, British Columbia – August 2nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high clinical and endoscopic response rates in its recently completed Phase 2, open-label, dose ranging trial in study participants with moderate to severe Ulcerative Colitis. In the study, 8 of 11 (73%) QBECO SSI treated participants achieved clinical response and 5 patients (45%) had endoscopic healing within the first 16 weeks of treatment with one patient in clinical and endoscopic remission by study week 8[1]. Importantly, histological improvement occurred in 6 of 11 (55%) trial participants, including 6 of 8 (75%) responders.
Dr. Hal Gunn, CEO of Qu Biologics, commented, “While this is a small study, we are very encouraged by the clinical and endoscopic responses that were achieved in patients treated with QBECO SSI. We are particularly excited about the endoscopic and histological responses that were observed as it appears that QBECO SSI treatment can result in symptom relief and healing at the mucosal and tissue levels.” Dr. Gunn added, “Research has demonstrated that histological improvement is correlated with improved long-term outcome in ulcerative colitis, including reduction in hospitalizations and surgery, and so we are particularly pleased that our novel treatment may have long lasting therapeutic impact in this challenging disease.”
As Jim Pankovich, Qu Biologics’ VP Clinical Operations and Drug Development noted, “This study is the first indication that treatment with QBECO SSI can result in clinical, endoscopic and histological improvement, all important outcome criteria in our ulcerative colitis program and overall inflammatory bowel disease development program. “
These data add to the body of knowledge and understanding Qu Biologics is generating about the use of QBECO SSI for the treatment of inflammatory bowel disease. Further data evaluation from the study is ongoing, including analysis of immune marker changes and correlation between patient genetics and response to QBECO treatment.
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.